Event Type: Q2 and H1 FY27 Earnings Conference Call and Analyst Meet.

Date and Time: The event was held on October 27, 2026. The specific time and time zone were not disclosed in the provided transcript.

Purpose: The stated purpose was to discuss the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended September 30, 2026, and provide a strategic and operational update.

Management Participants: The following management representatives participated:

  • Mr. Bikramjit Ghosh – Vice President, Strategy and Business Development
  • Mr. Dharmesh Thaker – Chief Financial Officer
  • Mr. Bharat Soni – Company Secretary
  • Ms. Pushpa Ponmany – Manager

The call was moderated by Ms. Sejal from MUFG Intime.

Availability of Materials: The full transcript of the conference call was made available on the company's website at https://sakarhealthcare.com/wpcontent/uploads/2026/11/Sakar-Q2-FY27-Earnings-Conference-Call-Transcript.pdf and was formally submitted to the stock exchange on November 2, 2026.

Financial Period Discussed: The discussion focused on the financial and operational performance for Q2 FY27 (quarter ended September 30, 2026) and H1 FY27 (half-year ended September 30, 2026).

Forward-Looking Statements & Strategic Themes: Management provided forward-looking commentary, including:

  • Expectation that the oncology business will contribute over 60% of revenue in the next 2-3 years.
  • Targeting revenue growth of 35%+ in the oncology business for FY28.
  • Expectation to achieve an EBITDA margin of 30-35% in the future, driven by full API integration.
  • Anticipated EU GMP certificate receipt within Q3 FY27 (by December 2026).

Compliance Language: The call began with a standard disclaimer that it may contain forward-looking statements based on the company's business opinions and expectations as of the date of the call.

Key Financial & Operational Highlights from the Call

Financial Performance for Q2 FY27:

  • Revenue from Operations: INR 8,741.61 lakhs (INR 87.42 Cr), up 52% Year-on-Year (YoY).
  • EBITDA: INR 2,434.53 lakhs (INR 24.35 Cr), up 114% YoY.
  • EBITDA Margin: 28%, improved from 20% in the year-ago period.
  • Profit After Tax (PAT): INR 1,130.69 lakhs (INR 11.31 Cr), up 149% YoY.

Financial Performance for H1 FY27:

  • Revenue from Operations: INR 16,038.86 lakhs (INR 160.39 Cr), up 45% YoY.
  • EBITDA: INR 4,559.42 lakhs (INR 45.59 Cr), up 90% YoY.
  • EBITDA Margin: 28%, expanded from 22%.
  • Profit After Tax (PAT): INR 2,159.18 lakhs (INR 21.59 Cr), up 134% YoY.

Oncology Business Breakdown (Q2 FY27):

  • Total Oncology Revenue: ~INR 50 Crores.
  • Domestic Oncology Sales: ~INR 43 Crores (includes deemed exports for partners).
  • Direct Export Oncology Sales: INR 8.2 Crores.
  • Within exports, ~INR 3.5 Cr was from own registrations and ~INR 4.7 Cr from CDMO business.

Oncology Business Breakdown (H1 FY27):

  • Total Oncology Revenue: ~INR 85 Crores.
  • External Oncology API Sales: INR 36-37 Crores.

Operational and Regulatory Progress:

  • Executed 69 oncology product contracts, with discussions ongoing for 45 more.
  • Shared 351 oncology dossiers globally.
  • 191 regulatory submissions made.
  • 22 Marketing Authorizations (MAs) granted (11 in Europe/UK, 6 in LatAm, 4 in Myanmar, 1 in Canada).
  • 36 European MA filings completed (16 proprietary).
  • 33 site variations submitted for 18 molecules; 11 approved in EU/UK.
  • Accord received 6 additional EMA site variation approvals (total 8/11 molecules).
  • 3 additional approvals received via partners in UK and Germany.
  • 33 CDMO technology transfer projects ongoing with 4 partners.
  • Developed 21 oncology APIs in-house (16 with written confirmation).
  • 8 products commercialized from in-house APIs.
  • 2 CEP applications approved, 5 in process.
  • Commercial supplies have commenced from the EU GMP-approved oncology facility.

Capacity Utilization:

  • New Bavla Plant: ~26%
  • Changodar Facility: ~36-37% (H1 FY27)

Response to Regulatory Query (NPPA Cap): Management clarified that the recent government notification capping trade margins on 137 non-scheduled anti-cancer drugs by 30% does not impact the company directly as it is a manufacturer and operates via principals in the domestic market.

Additional Notes

  • The document provided was the formal submission of the conference call transcript to the National Stock Exchange of India Ltd. under Regulation 30 of SEBI LODR Regulations, 2015.
  • The transcript included the full question-and-answer session with analysts, providing detailed insights into financials, strategy, and outlook.
  • No standalone financial data was disclosed in the announcement header; all figures were contained within the attached transcript.